MGD007
Phase 1Small molecule
MGD007 is one of 69 small molecule programs targeting Colorectal Carcinoma. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
698 competitors in Metastatic Colorectal Cancer
#DrugCompanyPhaseTrials
1Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Sutent
PfizerPhase 3
Trifluridine/tipiracil
AbbViePhase 3
Zocor
OOrganon and Co
Phase 3
Cosela
PPharmacosmos A/S
Phase 3
Legalon
BBukwang Pharmaceutical
Phase 3
Vatalanib
NovartisPhase 3
XL092
RochePhase 3
FOLFOX 2d
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Oxaliplatin, /m2
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MGD007. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MMacroGenics